ANDA 205134, held by Actavis Mid Atlantic. Hydrocortisone Butyrate.
As of Nov 21, 2026, ANDA 205134 (Hydrocortisone Butyrate), held by Actavis Mid Atlantic, was first approved by FDA on Dec 8, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 8, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrocortisone Butyrate0.1% · cream;topical | Hydrocortisone Butyrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters